183 related articles for article (PubMed ID: 36147906)
1. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma.
Lu H; Zheng LY; Wu LY; Chen J; Xu N; Mi SC
Front Oncol; 2022; 12():978921. PubMed ID: 36147906
[TBL] [Abstract][Full Text] [Related]
2. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.
Tan Z; Lei Y; Zhang B; Shi S; Liu J; Yu X; Xu J; Liang C
Front Oncol; 2021; 11():674897. PubMed ID: 34367961
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.
Cai W; Bao W; Chen S; Yang Y; Li Y
Cancer Cell Int; 2021 Dec; 21(1):698. PubMed ID: 34930261
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
6. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.
Zhu ZG; Chen L; Miao DL; Jin Y; Wu Q
Front Genet; 2022; 13():941389. PubMed ID: 36046234
[No Abstract] [Full Text] [Related]
7. Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients.
Zhang D; Wang M; Peng L; Yang X; Li K; Yin H; Xia C; Cui F; Huang H; Jin Z
J Oncol; 2021; 2021():4986227. PubMed ID: 34987579
[TBL] [Abstract][Full Text] [Related]
8. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract][Full Text] [Related]
9. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
10. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
11. Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma.
Zhao JG; Li YJ; Wu Y; Zhang K; Peng LJ; Chen H
BMC Med Genomics; 2023 May; 16(1):106. PubMed ID: 37198621
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
13. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
Ren M; Feng L; Zong R; Sun H
World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
[TBL] [Abstract][Full Text] [Related]
14. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma.
Liu Q; Li R; Wu H; Liang Z
BMC Cancer; 2023 Mar; 23(1):226. PubMed ID: 36894917
[TBL] [Abstract][Full Text] [Related]
15. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
Front Immunol; 2021; 12():769047. PubMed ID: 34777388
[TBL] [Abstract][Full Text] [Related]
18. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
[TBL] [Abstract][Full Text] [Related]
19. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment.
Pu N; Chen Q; Gao S; Liu G; Zhu Y; Yin L; Hu H; Wei L; Wu Y; Maeda S; Lou W; Yu J; Wu W
Ann Transl Med; 2019 Nov; 7(22):645. PubMed ID: 31930046
[TBL] [Abstract][Full Text] [Related]
20. The expression of m
Yao Y; Luo L; Xiang G; Xiong J; Ke N; Tan C; Chen Y; Liu X
Gland Surg; 2022 Jan; 11(1):147-165. PubMed ID: 35242677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
